Skip to main content

Table 1 Patient characteristics

From: Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients

  AML Myeloid Neoplasms (Non-AML)
Total 51 7
Subtype (%) AML with recurrent MDS-MLD: 2
  genetic abnormalities: 20 (39) MDS-EB-2: 1
  AML-MRC: 22 (43) CMML-2: 1
  t-AML: 4 (8) MDS/MPN: 2
  AML, NOS: 5 (10) CNL: 1
Age (years; median and range) 63 (20–86) 69 (42–84)
Sex   
 Male 25 4
 Female 26 3
EZH2-mutated patients (%) 6 (12) 7 (100)
Mutations per patient (median and range) 3 (0–7) 4 (3–7)
Del(7q) or -7 (%) 13 (25) 2 (29)
WBC (× 109/L; median and range) 10.4 (0.6–192.6) 18.4 (1.6–126.5)
BM blasts (%; median and range) 63 (10–100) 4 (1–16)
Treatment   
 Induction chemotherapy (%) 31 (61) 0
 HSCT (%) 27 (53) 4 (57)
 Non-intensive therapy (%) 13 (25) 3 (43)
  1. AML-MRC acute myeloid leukemia with myelodysplasia-related changes, BM bone marrow, CMML chronic myelomonocytic leukemia, CNL chronic neutrophilic leukemia, HSCT hematopoietic stem cell transplantation, MDS-EB myelodysplastic syndrome with excess blasts, MDS-MLD MDS with multilineage dysplasia, MPN myeloproliferative neoplasm, NOS not otherwise specified, WBC white blood cells, t-AML therapy-related AML